TP53 mutations have been implicated in aggressive tumor behavior and poor overall survival across multiple types of cancer, including colorectal cancer.46,47TP53 mutations have been observed in 65.5% of colorectal neuroendocrine carcinomas, with missense mutations being observed most frequently.36 Similarly, TP53 mutations, identified in 78% of tumors in one study,45 are highly prevalent in lung large-cell neuroendocrine carcinoma. The gene discussed is TP53; the disease is pulmonary large cell neuroendocrine carcinoma.